Asset Details
Do you wish to reserve the book?
Refillable Susvimo implant gains FDA approval
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Refillable Susvimo implant gains FDA approval
Do you wish to request the book?
Refillable Susvimo implant gains FDA approval
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Trade Publication Article
Refillable Susvimo implant gains FDA approval
2021
Overview
According to Awh, patients enrolled in Archway had received a mean of 5 anti-VEGF injections prior to study enrollment and had good baseline vision. Prespecified ocular adverse events of special interest were more common in the Susvimo arm than in the control group during the first 40 weeks of the trial (19.0% vs 6.0%). [...]it is hoped that appropriate management of the conjunctiva, including early detection of retraction and prompt surgical repair, may reduce the risk of endophthalmitis.\" [...]Awh said most of the other ocular adverse events occurred within the first month after the implantation procedure.
Publisher
MultiMedia Healthcare Inc
Subject
